The SIRveNIB Study
The Asian SIRveNIB Study, with 360-patients, showed that compared with the standard treatment of sorafenib, local treatment of advanced or inoperable Hepatocellular Carcinoma (HCC) with SIR-Spheres® Y-90 resin microspheres:
- did not show a significant improvement in overall survival
- had a significantly reduced frequency and severity of adverse events
- was significantly better tolerated
- significantly improved PFS and TTP, overall and in the liver, in the treated population
Chow PKH et al. J Clin Oncol 2018 Mar 2; ePub doi: 10.1200/JCO.2017.76.0892.